Drug development in inflammatory bowel disease: The role of the FDA

Has the FDA Amendments Act of 2007 Impaired Drug Development?

(2011) T R Franson   CLINICAL PHARMACOLOGY & THERAPEUTICS

Biosimilar epoetins and other “follow-on” biologics: Update on the European experiences

(2010) Wolfgang Jelkmann   AMERICAN JOURNAL OF HEMATOLOGY

Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009

(2010) K I Kaitin et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Once-daily mesalamine granules for ulcerative colitis

(2010) Garrett Lawlor et al.   Expert Review of Clinical Immunology

Hearing shines spotlight on biosimilar controversies

(2010) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Colchicine's Other Indication — Effect of FDA Action

(2010) Wayne W. Grody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incentives for Drug Development — The Curious Case of Colchicine

(2010) Aaron S. Kesselheim et al.   NEW ENGLAND JOURNAL OF MEDICINE

Innovation, Regulation, and the FDA

(2010) Margaret A. Hamburg   NEW ENGLAND JOURNAL OF MEDICINE

Placebo therapy in Crohn's disease

(2009) Sara Renna et al.   European Journal of Internal Medicine

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

(2009) Filip Baert et al.   GASTROENTEROLOGY

Controversies in mucosal healing in ulcerative colitis

(2009) Sunanda Kane et al.   INFLAMMATORY BOWEL DISEASES

Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease

(2008) Jennifer Jones et al.   Clinical Gastroenterology and Hepatology

Improving Delivery of Aminosalicylates in Ulcerative Colitis

(2008) Nielsen Q Fernandez-Becker et al.   DRUGS